All data are based on the daily closing price as of June 27, 2025
k

kyowa Kirin

4151.TSE
16.93 USD
-0.25
-1.46%

Overview

Last close
16.93 usd
Market cap
8.86B usd
52 week high
22.86 usd
52 week low
13.42 usd
Target price
17.56 usd

Valuation

P/E
25.0615
Forward P/E
16.6389
Price/Sales
2.5862
Price/Book Value
1.5388
Enterprise Value
7.35B usd
EV/Revenue
2.1504
EV/EBITDA
10.0381

Key financials

Revenue TTM
3.42B usd
Gross Profit TTM
2.51B usd
EBITDA TTM
761.68M usd
Earnings per Share
0.67 usd
Dividend
0.4 usd
Total assets
6.84B usd
Net debt
-1.29B usd

About

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, sells, and import/export of pharmaceuticals products worldwide. It's pipeline consist of OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4083/AMG 45, which is in Phase III and II clinical trial for the treatment of atopic dermatitis and prurigo nodularis, and asthma; OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A; ziftomenib, which is in Phase II and I clinical trial for the treatment of acute myeloid Leukemia and acute lymphoblastic leukemia; KHK4951, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; KK8123, which is in Phase I clinical trial for the treatment of x-linked hypophosphatemia; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK4277, which is in Phase I clinical trial for the treatment of systemic and cutaneous lupus erythematosus; and KK2260 and KK2269 that are in Phase I clinical trial for the treatment of solid tumors. It also develops POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein that produces platelet; Crysvita, a recombinant human monoclonal IgG1 antibody; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and LUMICEF, a biological treatment for moderate to severe plaque psoriasis. In addition, it offers G-Lasta; Duvroq; PHOZEVEL; KK8398; KHK4827; and OTL-200. It has an agreement with Amgen Inc. and Kura Oncology. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
  • Symbol
    4151.TSE
  • Exchange
    TSE
  • Isin
    JP3256000005
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - General
  • CEO
    Mr. Masashi Miyamoto Ph.D.
  • Headquarter
    Tokyo
  • Web site
    https://www.kyowakirin.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top